We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
No events to show.
Consensus vs. actual, and revenue trend
Rating & price-target changes
Stored first · Google News · Yahoo Finance (English)
How Novartis optimized its supply chain - EY
How Novartis optimized its supply chain EY
Novartis marks 30 years of breakthroughs, building on 250 years of discovery to reimagine what medicine can do next - Novartis
Novartis marks 30 years of breakthroughs, building on 250 years of discovery to reimagine what medicine can do next Novartis
Peptidream Inc. - Initiation Of Phase 1 Clinical Trial By Novartis Marks Milestone For Peptidream - TradingView
Peptidream Inc. - Initiation Of Phase 1 Clinical Trial By Novartis Marks Milestone For Peptidream TradingView
Kolchinsky Warns Ban on Chinese Biotech Deals Would Hand Pipeline to Novartis - finance.biggo.com
Kolchinsky Warns Ban on Chinese Biotech Deals Would Hand Pipeline to Novartis finance.biggo.com
Erste Group Bank Forecasts Weaker Earnings for Novartis - MarketBeat
Erste Group Bank Forecasts Weaker Earnings for Novartis MarketBeat
Small shifts. Big impact. The leadership choices that matter most in the age of AI - Novartis
Small shifts. Big impact. The leadership choices that matter most in the age of AI Novartis
No earnings data to show.
No research actions to show.
Price data
No holdings data to show.